HBM Healthcare Investments elected to exercise pre-funded warrants tied to its voting obligations in Chemomab Therapeutics, reporting beneficial ownership of 80,971,680 ordinary shares, equal to 12.5%. The move matters because the Warrant election is expressly intended to effectuate HBM’s obligations under the Shareholder Support Agreement.

Key Highlights

  • Each American Depositary Share held by HBM represents 80 Chemomab ordinary shares.
  • Voting and Investment power over HBM’s position rests with its board of directors.
  • HBM sent Chemomab formal notice of the warrant election on September 7, 2026.

HBM Healthcare Investments (Cayman) Ltd. reports beneficial ownership of 80,971,680 ordinary shares in Chemomab Therapeutics Ltd. (NASDAQ: CMMB), representing 12.5% of the company’s ordinary shares.

HBM’s Ownership Structure

HBM holds American Depositary Shares, with each ADS representing 80 ordinary shares of Chemomab. The underlying ordinary shares carry no par value, and beneficial ownership is reported using those ordinary shares rather than the ADSs. Voting and investment authority over the ordinary shares represented by HBM’s ADSs is exercised by HBM’s board. None of the directors has individual voting or investment power over the represented ordinary shares.

Warrant Election Tied to Support Agreement

HBM sent formal notice to Chemomab on September 7, 2026, regarding its election to exercise the pre-funded warrants. The ownership statement was signed by Jean-Marc LeSieur, HBM’s managing director, on September 9, 2026.